1/21/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Lepheton-Desentol AB Unimedic

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Efedrin

Efedrin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Hughes SC, Ward MG, Levinson G, Shnider SM, Wright RG, Gruenke LD et al. Placental transfer of ephedrine does not affect neonatal outcome. Anesthesiology. 1985;63:217-9.

  2. Wright RG, Shnider SM, Levinson G, Rolbin SH, Parer JT. The effect of maternal administration of ephedrine on fetal heart rate and variability. Obstet Gynecol. 1981;57:734-8.

  3. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  1. Hughes SC, Ward MG, Levinson G, Shnider SM, Wright RG, Gruenke LD et al. Placental transfer of ephedrine does not affect neonatal outcome. Anesthesiology. 1985;63:217-9.
  2. Wright RG, Shnider SM, Levinson G, Rolbin SH, Parer JT. The effect of maternal administration of ephedrine on fetal heart rate and variability. Obstet Gynecol. 1981;57:734-8.
  3. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
2 2
2 2

Difenhydramin

Difenhydramin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  2. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.

  3. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.

  4. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94(1):22-30.

  5. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A, National Birth Defects Prevention Study. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol. 2009;85(2):137-50.

  6. Li Q, Mitchell AA, Werler MM, Yau WP, Hernández-Díaz S. Assessment of antihistamine use in early pregnancy and birth defects. J Allergy Clin Immunol Pract. 2013;1(6):666-74e1.

  7. Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121-132.

  8. Parkin DE. Probable Benadryl withdrawal manifestations in a newborn infant. J Pediatr. 1974;85(4):580.

  9. Miller AA. Diphenhydramine toxicity in a newborn: a case report. J Perinatol. 2000;20(6):390-1.

  10. Abernathy A, Alsina L, Greer J, Egerman R. Transient Fetal Tachycardia After Intravenous Diphenhydramine Administration. Obstet Gynecol. 2017;130(2):374-376.

  11. Brost BC, Scardo JA, Newman RB. Diphenhydramine overdose during pregnancy: lessons from the past. Am J Obstet Gynecol. 1996;175(5):1376-7.

  12. Shenai N, Shulman J, Gopalan P, Cheng E, Cerimele JM. Fetal Outcomes in Intentional Over-the-Counter Medication Overdoses in Pregnancy. Psychosomatics. 2018;59(4):400-404.

  1. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  2. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.
  3. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.
  4. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94(1):22-30.
  5. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A, National Birth Defects Prevention Study. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol. 2009;85(2):137-50.
  6. Li Q, Mitchell AA, Werler MM, Yau WP, Hernández-Díaz S. Assessment of antihistamine use in early pregnancy and birth defects. J Allergy Clin Immunol Pract. 2013;1(6):666-74e1.
  7. Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121-132.
  8. Parkin DE. Probable Benadryl withdrawal manifestations in a newborn infant. J Pediatr. 1974;85(4):580.
  9. Miller AA. Diphenhydramine toxicity in a newborn: a case report. J Perinatol. 2000;20(6):390-1.
  10. Abernathy A, Alsina L, Greer J, Egerman R. Transient Fetal Tachycardia After Intravenous Diphenhydramine Administration. Obstet Gynecol. 2017;130(2):374-376.
  11. Brost BC, Scardo JA, Newman RB. Diphenhydramine overdose during pregnancy: lessons from the past. Am J Obstet Gynecol. 1996;175(5):1376-7.
  12. Shenai N, Shulman J, Gopalan P, Cheng E, Cerimele JM. Fetal Outcomes in Intentional Over-the-Counter Medication Overdoses in Pregnancy. Psychosomatics. 2018;59(4):400-404.
2 2
2 2

Etylmorfin

Etylmorfin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-31.

  2. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.

  3. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107 Suppl 1:53-62.

  4. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Childh 2004;89:F33-F36.

  5. Finnegan LP. Pathophysiological and behavioural effects of the transplacental transfer of narcotic drugs to the foetuses and neonates of narcotic-dependent mothers. Bull Narc 1979;31:1-58.

  6. Viatris. Cocillana-Etyfin Produktresumé. Läkemedelsverket [www]. [updated 2022-04-05, cited 2022-12-12].

  1. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-31.
  2. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.
  3. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107 Suppl 1:53-62.
  4. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Childh 2004;89:F33-F36.
  5. Finnegan LP. Pathophysiological and behavioural effects of the transplacental transfer of narcotic drugs to the foetuses and neonates of narcotic-dependent mothers. Bull Narc 1979;31:1-58.
  6. Viatris. Cocillana-Etyfin Produktresumé. Läkemedelsverket [www]. [updated 2022-04-05, cited 2022-12-12].